摘要
目的:分析"4+7"带量采购对SSRI类抗抑郁药使用的影响,为政策制定和医院药事管理提供参考。方法:采用药物经济学方法对"4+7"实施后6个月和2018年同期6个月门诊SSRI类抗抑郁药的数量、金额、用药频度(DDDs)、日均费用(DDC)等进行分析。结果:"4+7"后,艾司西酞普兰片数显著增长,帕罗西汀金额明显下降。艾司西酞普兰的DDDs值增幅较大。艾司西酞普兰和帕罗西汀的DDC值较去年同期都下降明显。结论:本次"4+7"政策落地半年,切实降低了部分患者的用药负担,提升了医保基金的使用效率。
OBJECTIVE To analyze the influence of the pharmaceutical procurement with target quantity("4+7")of selective serotonin reuptake inhibitors(SSRIs), and to provide reference for policy formulation and hospital drug management.METHODS The method of pharmacoeconomics was used to analyze sales amount, sales volume, defined daily doses(DDDs), defined daily cost(DDC) of 6 months after implementation of "4+7" and corresponding period of 2018.RESULTS After the implementation of "4+7", the usage volume of escitalopram was substantially increased, and the sales amount of paroxetine was sharply decreased. The DDDs of escitalopram were increased significantly, while the DDC of escitalopram and paroxetine were decreased significantly.CONCLUSION The implementation of the "4+7" policy for half a year has effectively reduced the medication burden of some patients and improved the use efficiency of medical insurance fund.
作者
杨琪
臧彦楠
庄红艳
果伟
YANG Qi;ZANG Yan-nan;ZHUANG Hong-yan;GUO Wei(The National Clinical Research Center for Mental Disorders&Beijing Key Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical University,Beijing 100088,China;Advanced Innovation Center for Human Brain Protection,Capital Medical University,Beijing 100069,China)
出处
《中国医院药学杂志》
CAS
北大核心
2020年第13期1479-1483,共5页
Chinese Journal of Hospital Pharmacy
基金
首都卫生发展科研专项(编号:2018-4-2124)
北京市属医院科研培育计划(编号:PX2019069)。
关键词
带量采购
选择性5-羟色胺再摄取抑制剂类(SSRIs)
用药频度
日用药金额
the pharmaceutical procurement with target quantity
selective serotonin reuptake inhibitors
defined daily doses(DDDs)
defined daily cost(DDC)